raptor pharmaceutical corp (RPTP) Snapshot

Raptor Pharmaceutical Corp. announced that PROCYSBI(TM) (cysteamine bitartrate) delayed-release capsules are now available in the U.S. for shipment to cystinosis patients. The U.S. Food and Drug Administration (FDA) approved PROCYSBI on April 30, 2013 for the management of nephropathic cystinosis in adults and children ages 6 years and older. Initial prescription claims have been approved by multiple payor categories and PROCYSBI is being shipped to patients. Physicians can prescribe PROCYSBI by calling RaptorCares at 1-855-888-4004. RaptorCares provides individualized services to help patients access PROCYSBI through education, support, extensive case management and a commitment to the principle that no eligible U.S. patient with nephropathic cystinosis will be denied access to PROCYSBI based on inability to pay.

Raptor Pharmaceuticals Corp. reported unaudited consolidated financial results for the first quarter ended March 31, 2013. Net loss for the first quarter ended March 31, 2013 was $15.9 million, or $0.30 per basic and diluted share compared to a net loss of $14.0 million or $0.29 per basic and diluted share for the fiscal quarter ended February 29, 2012. Loss from operations was $16.275 million against $6.423 million a year ago.

Raptor Pharmaceuticals Corp. announced that the U.S. Food and Drug Administration has approved PROCYSBI (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.